<DOC>
	<DOC>NCT02943031</DOC>
	<brief_summary>This is a prospective cohort study. Patients who meet the inclusion criteria will be enrolled in this study. The samples of biliary tract tumors will be collected. Genome sequencing, mini-PDX and PDX will be performed according to the requirement of individualized precision therapy programs. Suitable drugs will be chose according to drug screening results. OS and PFS will be compared with traditional chemotherapy to evaluate the effect of individualized precision therapy programs.</brief_summary>
	<brief_title>The Effect of Individualized Precision Therapy Programs in Patients With BTC</brief_title>
	<detailed_description>In this prospective cohort study, patients who are eligible for inclusion criteria will enroll in the study. After bile duct tumor samples were collected, whole genome sequencing, drug screening ( including Mini-PDX and PDX) will conduct. Suitable drugs will be decided according to the different genomics classification, and then to develop individualized precise treatment programs. The investigators hope to achieve the following objectives: ① Through the establishment of Individualized Precision Therapy Programs to improve the overall survival of bile duct malignancy (BTC)； ② To study the molecular typing of the prognosis of biliary malignancy; ③ To construct a database of BTC gene bank, as well as for drug screening information.</detailed_description>
	<mesh_term>Biliary Tract Neoplasms</mesh_term>
	<criteria>Pathological diagnosis of biliary malignancies The expected survival time is longer than 3 months PKS score&gt; 60 points Willing to take part in the study Can not or refuse to collect tumor samples Refused to accept the relevant treatment method</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>bile duct tumor</keyword>
	<keyword>individualized precise treatment programs</keyword>
</DOC>